These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 34153986)

  • 21. Assessment of plasma lyso-Gb
    Bichet DG; Aerts JM; Auray-Blais C; Maruyama H; Mehta AB; Skuban N; Krusinska E; Schiffmann R
    Genet Med; 2021 Jan; 23(1):192-201. PubMed ID: 32994552
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetics and Gene Therapy of Anderson-Fabry Disease.
    Simonetta I; Tuttolomondo A; Di Chiara T; Miceli S; Vogiatzis D; Corpora F; Pinto A
    Curr Gene Ther; 2018; 18(2):96-106. PubMed ID: 29618309
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pathogenesis and Molecular Mechanisms of Anderson-Fabry Disease and Possible New Molecular Addressed Therapeutic Strategies.
    Tuttolomondo A; Simonetta I; Riolo R; Todaro F; Di Chiara T; Miceli S; Pinto A
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576250
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of Fabry Disease management with migalastat-outcome from a prospective 24 months observational multicenter study (FAMOUS).
    Lenders M; Nordbeck P; Kurschat C; Eveslage M; Karabul N; Kaufeld J; Hennermann JB; Patten M; Cybulla M; Müntze J; Üçeyler N; Liu D; Das AM; Sommer C; Pogoda C; Reiermann S; Duning T; Gaedeke J; von Cossel K; Blaschke D; Brand SM; Mann WA; Kampmann C; Muschol N; Canaan-Kühl S; Brand E
    Eur Heart J Cardiovasc Pharmacother; 2022 May; 8(3):272-281. PubMed ID: 35512362
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systematic gene therapy derived from an investigative study of AAV2/8 vector gene therapy for Fabry disease.
    Deng M; Zhou H; He S; Qiu H; Wang Y; Zhao AY; Mu Y; Li F; Zhao AZ
    Orphanet J Rare Dis; 2023 Sep; 18(1):275. PubMed ID: 37670350
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human α-Galactosidase A Mutants: Priceless Tools to Develop Novel Therapies for Fabry Disease.
    Modrego A; Amaranto M; Godino A; Mendoza R; Barra JL; Corchero JL
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34204583
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mutation-specific Fabry disease patient-derived cell model to evaluate the amenability to chaperone therapy.
    Lenders M; Stappers F; Niemietz C; Schmitz B; Boutin M; Ballmaier PJ; Zibert A; Schmidt H; Brand SM; Auray-Blais C; Brand E
    J Med Genet; 2019 Aug; 56(8):548-556. PubMed ID: 31010832
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Switch from enzyme replacement therapy to oral chaperone migalastat for treating fabry disease: real-life data.
    Riccio E; Zanfardino M; Ferreri L; Santoro C; Cocozza S; Capuano I; Imbriaco M; Feriozzi S; Pisani A;
    Eur J Hum Genet; 2020 Dec; 28(12):1662-1668. PubMed ID: 32647377
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase II, multicenter, open-label trial to evaluate the safety and efficacy of ISU303 (Agalsidase beta) in patients with Fabry disease.
    Hwang S; Lee BH; Kim WS; Kim DS; Cheon CK; Lee CH; Choi Y; Choi JH; Kim JH; Yoo HW
    Medicine (Baltimore); 2022 Sep; 101(37):e30345. PubMed ID: 36123934
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Globotriaosylsphingosine (lyso-Gb
    Effraimidis G; Feldt-Rasmussen U; Rasmussen ÅK; Lavoie P; Abaoui M; Boutin M; Auray-Blais C
    J Med Genet; 2021 Oct; 58(10):692-700. PubMed ID: 32963035
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Migalastat: A Review in Fabry Disease.
    McCafferty EH; Scott LJ
    Drugs; 2019 Apr; 79(5):543-554. PubMed ID: 30875019
    [TBL] [Abstract][Full Text] [Related]  

  • 32.
    Kytidou K; Beekwilder J; Artola M; van Meel E; Wilbers RHP; Moolenaar GF; Goosen N; Ferraz MJ; Katzy R; Voskamp P; Florea BI; Hokke CH; Overkleeft HS; Schots A; Bosch D; Pannu N; Aerts JMFG
    J Biol Chem; 2018 Jun; 293(26):10042-10058. PubMed ID: 29674318
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diurnal Variation of Urinary Fabry Disease Biomarkers during Enzyme Replacement Therapy Cycles.
    Boutin M; Lavoie P; Menkovic I; Toupin A; Abaoui M; Elidrissi-Elawad M; Arthus MF; Fortier C; Ménard C; Maranda B; Bichet DG; Auray-Blais C
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32854306
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The use of agalsidase alfa enzyme replacement therapy in the treatment of Fabry disease.
    Morel CF; Clarke JT
    Expert Opin Biol Ther; 2009 May; 9(5):631-9. PubMed ID: 19368525
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The prevalence of Fabry disease among 1009 unrelated patients with hypertrophic cardiomyopathy: a Russian nationwide screening program using NGS technology.
    Savostyanov K; Pushkov A; Zhanin I; Mazanova N; Trufanov S; Pakhomov A; Alexeeva A; Sladkov D; Asanov A; Fisenko A
    Orphanet J Rare Dis; 2022 May; 17(1):199. PubMed ID: 35578305
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fabry Disease: Molecular Basis, Pathophysiology, Diagnostics and Potential Therapeutic Directions.
    Kok K; Zwiers KC; Boot RG; Overkleeft HS; Aerts JMFG; Artola M
    Biomolecules; 2021 Feb; 11(2):. PubMed ID: 33673160
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lyso-Gb3 associates with adverse long-term outcome in patients with Fabry disease.
    Nowak A; Beuschlein F; Sivasubramaniam V; Kasper D; Warnock DG
    J Med Genet; 2022 Mar; 59(3):287-293. PubMed ID: 33495303
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reduced glucosylceramide in the mouse model of Fabry disease: correction by successful enzyme replacement therapy.
    Quinta R; Rodrigues D; Assunção M; Macedo MF; Azevedo O; Cunha D; Oliveira P; Sá Miranda MC
    Gene; 2014 Feb; 536(1):97-104. PubMed ID: 24334116
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fabry Disease Therapy: State-of-the-Art and Current Challenges.
    Azevedo O; Gago MF; Miltenberger-Miltenyi G; Sousa N; Cunha D
    Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33379210
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Ckd. Qld fabRy Epidemiology (aCQuiRE) study protocol: identifying the prevalence of Fabry disease amongst patients with kidney disease in Queensland, Australia.
    Mallett A; Kearey P; Cameron A; Healy H; Denaro C; Thomas M; Lee VW; Stark S; Fuller M; Hoy WE
    BMC Nephrol; 2020 Feb; 21(1):58. PubMed ID: 32087678
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.